Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry - Scorecard - MDSpire

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

  • By

  • Amy S. Paller

  • Danielle Marcoux

  • Michele Ramien

  • Eulalia Baselga

  • Vania Oliveira de Carvalho

  • Ledit R. F. Ardusso

  • Marlies de Graaf

  • Suzanne Pasmans

  • Mirna Toledo-Bahena

  • Cory J. Rubin

  • Joel C. Joyce

  • Lara Wine Lee

  • Rajan Gupta

  • Bryan Adams

  • Marius Ardeleanu

  • Annie Zhang

  • April 17, 2026

  • 0 min

Share

Clinical Scorecard: Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

At a Glance

CategoryDetail
ConditionModerate-to-Severe Atopic Dermatitis
Key MechanismsSystemic therapies targeting immune response
Target PopulationChildren aged 12 years and younger
Care SettingReal-world clinical settings

Key Highlights

  • Analysis based on data from the PEDISTAD Registry
  • Focus on systemic treatments for pediatric patients
  • Outcomes assessed include efficacy and safety
  • Emphasis on real-world treatment experiences
  • Insights into treatment patterns and patient demographics

Guideline-Based Recommendations

Diagnosis

  • Diagnosis should be based on clinical evaluation and history.

Management

  • Consider systemic therapies for moderate-to-severe cases not responding to topical treatments.

Monitoring & Follow-up

  • Regular follow-up to assess treatment efficacy and side effects.

Risks

  • Monitor for potential adverse effects associated with systemic therapies.

Patient & Prescribing Data

Children aged 12 years and younger with moderate-to-severe atopic dermatitis

Real-world outcomes indicate variability in treatment response.

Clinical Best Practices

  • Utilize a multidisciplinary approach for management.
  • Engage in shared decision-making with caregivers.
  • Tailor treatment plans based on individual patient needs.

References

Original Source(s)

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

  • by Amy S. Paller, Danielle Marcoux, Michele Ramien, Eulalia Baselga, Vania Oliveira de Carvalho, Ledit R. F. Ardusso, Marlies de Graaf, Suzanne Pasmans, Mirna Toledo-Bahena, Cory J. Rubin, Joel C. Joyce, Lara Wine Lee, Rajan Gupta, Bryan Adams, Marius Ardeleanu, Annie Zhang

  • April 17, 2026

Related Content

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

Case Report: Intravenous transplantation of autologous adipose tissue-derived mesenchymal stem cells attenuated atopic dermatitis

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.